RU94037235A - Ингибитор фиброза матки - Google Patents

Ингибитор фиброза матки

Info

Publication number
RU94037235A
RU94037235A RU94037235/14A RU94037235A RU94037235A RU 94037235 A RU94037235 A RU 94037235A RU 94037235/14 A RU94037235/14 A RU 94037235/14A RU 94037235 A RU94037235 A RU 94037235A RU 94037235 A RU94037235 A RU 94037235A
Authority
RU
Russia
Prior art keywords
inhibitor
fibrosis
uterus fibrosis
compound
formulawhere
Prior art date
Application number
RU94037235/14A
Other languages
English (en)
Other versions
RU2145851C1 (ru
Inventor
Джон Блэк Ларри
Us]
Джозеф Каллинан Джордж
Уильям Дрейпер Майкл
Дэвид Джоунз Чарлз
Эдвард Сейлер Дэвид
Original Assignee
Эли Лилли энд Компани (US)
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли энд Компани (US), Эли Лилли Энд Компани filed Critical Эли Лилли энд Компани (US)
Publication of RU94037235A publication Critical patent/RU94037235A/ru
Application granted granted Critical
Publication of RU2145851C1 publication Critical patent/RU2145851C1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)
  • Surgical Instruments (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

Описывается ингибирование фиброза матки, заключающееся в назначении человеку или другому млекопитающему, нуждающемуся в лечении, эффективного количества соединения формулы приведенной в описании.

Claims (1)

  1. Описывается ингибирование фиброза матки, заключающееся в назначении человеку или другому млекопитающему, нуждающемуся в лечении, эффективного количества соединения формулы приведенной в описании.
RU94037235A 1993-10-15 1994-10-13 Ингибитор фиброза матки RU2145851C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/138,642 US5457116A (en) 1993-10-15 1993-10-15 Methods of inhibiting uterine fibrosis
US08/138,642 1993-10-15

Publications (2)

Publication Number Publication Date
RU94037235A true RU94037235A (ru) 1996-11-10
RU2145851C1 RU2145851C1 (ru) 2000-02-27

Family

ID=22482959

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94037235A RU2145851C1 (ru) 1993-10-15 1994-10-13 Ингибитор фиброза матки

Country Status (23)

Country Link
US (1) US5457116A (ru)
EP (1) EP0651999B1 (ru)
JP (1) JPH07188015A (ru)
KR (1) KR950010892A (ru)
CN (1) CN1058389C (ru)
AT (1) ATE216582T1 (ru)
AU (1) AU680042B2 (ru)
CA (1) CA2118090A1 (ru)
CZ (1) CZ287247B6 (ru)
DE (1) DE69430465T2 (ru)
DK (1) DK0651999T3 (ru)
ES (1) ES2172525T3 (ru)
HU (1) HUT71236A (ru)
IL (1) IL111285A (ru)
NO (1) NO943878L (ru)
NZ (1) NZ264678A (ru)
PH (1) PH31596A (ru)
PT (1) PT651999E (ru)
RU (1) RU2145851C1 (ru)
SG (1) SG46324A1 (ru)
TW (1) TW327601B (ru)
UA (1) UA27883C2 (ru)
ZA (1) ZA948031B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
JPH08510451A (ja) 1993-05-13 1996-11-05 ネオルックス コーポレイション 異常増殖性平滑筋細胞に関連した病因の予防及び治療
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
AU6277396A (en) 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5670523A (en) * 1996-01-29 1997-09-23 Eli Lilly And Company Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
WO1997026878A1 (en) * 1996-01-29 1997-07-31 Eli Lilly And Company Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5827876A (en) * 1996-04-09 1998-10-27 American Home Products Corporation Inhibition of bone loss by 3-(4-acrylamidobenzoyl) benzo b!-thiophenes
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
EP1395563B1 (en) * 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US6962928B2 (en) * 2001-05-22 2005-11-08 Eli Lilly And Company Tetrahydroquinoline derivatives for the inhibition of osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US20080221163A1 (en) * 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
DE4122484A1 (de) * 1991-07-06 1993-01-07 Teves Gmbh Alfred Schaltungsanordnung zur erkennung von radsensordefekten
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5461065A (en) * 1993-10-15 1995-10-24 Eli Lilly And Company Methods for inhibiting endometriosis
US5418252A (en) * 1993-10-15 1995-05-23 Eli Lilly And Company Method for inhibiting cartilage degradation
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis

Also Published As

Publication number Publication date
CZ287247B6 (en) 2000-10-11
IL111285A0 (en) 1994-12-29
JPH07188015A (ja) 1995-07-25
CN1058389C (zh) 2000-11-15
ES2172525T3 (es) 2002-10-01
EP0651999B1 (en) 2002-04-24
IL111285A (en) 1998-12-27
NO943878D0 (no) 1994-10-13
PT651999E (pt) 2002-08-30
ATE216582T1 (de) 2002-05-15
SG46324A1 (en) 1998-02-20
PH31596A (en) 1998-11-03
UA27883C2 (uk) 2000-10-16
DK0651999T3 (da) 2002-06-17
CZ253894A3 (en) 1995-05-17
AU7583494A (en) 1995-05-04
EP0651999A1 (en) 1995-05-10
CA2118090A1 (en) 1995-04-16
NZ264678A (en) 1997-07-27
HU9402960D0 (en) 1995-02-28
AU680042B2 (en) 1997-07-17
RU2145851C1 (ru) 2000-02-27
ZA948031B (en) 1996-04-15
US5457116A (en) 1995-10-10
DE69430465T2 (de) 2002-10-31
KR950010892A (ko) 1995-05-15
CN1107156A (zh) 1995-08-23
HUT71236A (en) 1995-11-28
NO943878L (no) 1995-04-18
TW327601B (en) 1998-03-01
DE69430465D1 (de) 2002-05-29

Similar Documents

Publication Publication Date Title
RU94037235A (ru) Ингибитор фиброза матки
RU94045846A (ru) Применение производных бензотиофена для ингибирования тромбина
RU94036772A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования эндометриоза
RU94036758A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома
US5681835A (en) Non-steroidal ligands for the estrogen receptor
RU94045149A (ru) Средство ингибирования легочных гипертонических заболеваний
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
RU94044488A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования симптомов пременструального синдрома/ дисфории, связанной с поздней лютеальной фазой
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
RU94044454A (ru) Ингибитор аутоимунных заболеваний
RU94037246A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования разрушения хряща
RU94036771A (ru) Ингибиторы ангиогенеза и ангиогенных заболеваний
RU94045155A (ru) Способы ингибирования болезни альцгеймера
GB9900334D0 (en) Tricylic vascular damaging agents
HUP0004238A2 (hu) Farnezil-transzferáz inhibitor hatású imidazolszármazékok és eljárás előállításukra, valamint a vegyületeket tartalmazó gyógyszerkészítmények
RU94044453A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования себореи и угрей
RU94044456A (ru) Средство для подавления дисфункционального маточного кровотечения
RU94043811A (ru) Применение 2-фенил-3-ароилбензтиофенов для лечения менструальных симптомов, фармацевтические композиции
RU94045278A (ru) Применение 2-фенил-3-ароилбензтиофенов для ингибирования вазомоторных симптомов и сопутствующих психологических нарушений, ассоциированных с постклимактерическим синдромом
RU94044321A (ru) Средство повышения либидо у женщин постклимактерического периода
RU94037233A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения лекарственноустойчивых новообразований
RU94045277A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования расстройств цнс у женщин в постменопаузе
BR9807079A (pt) Composto de derivado de 16-hidróxi-11- (fenil substituìdo) - estra-4,9-dieno, uso de um composto, formulação farmacêutica, e processo para a preparação de um composto.
RU94044489A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования миелопероксидазной активности
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с